Results 81 to 90 of about 2,994 (188)

Delayed Recognition of Thrombotic Thrombocytopenic Purpura Following Platelet Transfusion: A Clinical Pitfall

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Thrombotic thrombocytopenic purpura (TTP) is a rare, life‐threatening thrombotic microangiopathy caused by severe ADAMTS13 deficiency, usually due to autoantibody‐mediated inhibition. Its presentation is heterogeneous and often lacks the classic pentad, leading to diagnostic delays. Neurological symptoms may predominate, masking the underlying
Abdulrahman Al‐Dawoudi, Mujahed Dalain, Daniil Varlamov, Shaghaf Alhallak, Dāvis Freimanis   +4 more
wiley   +1 more source

Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option

Nefrología (English Edition), 2017
Understanding the role of the complement system in the pathogenesis of atypical haemolytic uraemic syndrome and other thrombotic microangiopathies (TMA) has led to the use of anti-complement therapy with eculizumab in these diseases, in addition to its ...
Elena Román, Santiago Mendizábal, Isidro Jarque, Javier de la Rubia, Amparo Sempere, Enrique Morales, Manuel Praga, Ana Ávila, José Luis Górriz   +8 more
doaj   +1 more source

Thromboinflammatory biomarkers in obstetric pathophysiology: Predictive insights into placental insufficiency and feto‐maternal adverse outcomes

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Placental insufficiency is a thromboinflammatory disorder driven by angiogenic imbalance, complement activation, endothelial dysfunction and coagulation dysregulation, leading to microvascular thrombosis, impaired uteroplacental perfusion and adverse maternal and fetal outcomes, including pre‐eclampsia, fetal growth restriction and stillbirth. Abstract
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis

Haematologica, 2020
Agnès Veyradier
doaj   +1 more source

Rationale and Methods of a Surveillance System for Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies: A Qualitative Participatory Action Research Approach in Middle‐Income Countries—The Experience in Iran

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Hematopoietic Stem Cell Transplantation (HSCT) represents a cornerstone in the therapeutic management of hematological malignancies, aimed at achieving durable remission and enhancing survival. Optimal post‐transplant care, however, necessitates access to near‐real‐time, actionable clinical data.
Sima Oshnouei, Mohamad Jebraeily, Mohsen Asadi‐Lari, Babak Eshrati, Rahim Asghari, Masoumeh Nabivandrezaei, Ali Arash Anoushirvani, Aarefeh Jafarzadeh‐Kohneloo   +7 more
wiley   +1 more source

Trends in Clinical Indications for Plasma Exchange in Adult Patients Between 2008 and 2024 in Bogotá, Colombia

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT This multicenter retrospective study aimed to describe temporal trends in clinical indications for plasma exchange (PE) in adult patients at four quaternary‐care hospitals in Bogotá (2008–2024) and to examine their distribution across successive ASFA guideline editions.
Edgar Julián Reyes, Federico Tovar‐Avendaño, Camilo Alberto Gonzalez‐Gonzalez, Diana Carolina Vargas‐Angel, Jorge Pulido, Paula Violeta Rodríguez, Deiner‐Yivelson Muñoz‐Delgado, Kateir Contreras‐Villamizar   +7 more
wiley   +1 more source

Biomarkers of Endothelial Damage in Acute Graft‐Versus‐Host Disease After Allogenic Hematopoietic Stem Cell Transplantation: Methodological Challenges

Journal of Clinical Laboratory Analysis, Volume 40, Issue 15, August 2026.
Allogeneic hematopoietic stem cell transplantation remains a potentially curative therapy for many hematological malignancies; however, its success is significantly limited by acute graft‐versus‐host disease (aGVHD), a leading cause of post‐transplant morbidity and mortality in which endothelial dysfunction plays a central role.
Katarina Klinar, Helena Podgornik
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Effectiveness and Safety of Prophylactic Low‐Dose Emicizumab in Young Children With Hemophilia A: A Multicenter Retrospective Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Real‐world data on low‐dose emicizumab in young children with hemophilia A are limited. Methods This multicenter retrospective study included 26 children (median age: 2.2 years) receiving individualized low‐dose emicizumab (2019–2025).
Guichi Zhou, Liya He, Chunyan Wang, Yashuang Deng, Dong Peng, Zhaonan Liu, Sixi Liu, Xiaoying Fu, Ying Wang, Xiaoqin Feng   +9 more
wiley   +1 more source

Successful Full‐Term Pregnancy in Clinically Diagnosed Congenital Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Thrombotic thrombocytopenic purpura (TTP) is a rare, life‐threatening thrombotic microangiopathy resulting from severe ADAMTS13deficiency. Congenital TTP (cTTP, Upshaw–Schulman syndrome) arises from biallelic mutations in the ADAMTS13 gene, leading to lifelong enzyme deficiency, often manifesting in childhood and requiring chronic
Zahra Rahimi, Neda Hashemi, Elham Pishgar, Marziyeh Ghalamkari   +3 more
wiley   +1 more source